Tenet Diagnostics has raised approximately $30 million from Tata Capital Healthcare Fund III and Blue Earth Capital, a Switzerland-based impact investor. The equity stake, valuation, and split between the two investors have not been disclosed, and no board changes have been stated.
The capital flows into Tenet Medcorp Private Limited, which trades as Tenet Diagnostics. Talks between the two sides were first reported in March 2026, making this a five-month process from disclosure to close, and the deal is among the first investments from Tata Capital’s third healthcare fund since its first close earlier this year. The company said the money will help it deepen its footprint across India and expand access to diagnostics.
Founded in 2016 by Hanumantha Rao Ch, Surendranath C, Vinod P Nair, and Ram Pap Rao A, Tenet now runs a network of pathology and radiology centres across Telangana, Andhra Pradesh, Karnataka, Maharashtra, Bihar, Uttar Pradesh, Jharkhand and Odisha, offering imaging, lab testing, cardiology and neurology services including MRI, CT, PET-CT and mammography. The most recent public financials are from September 2023, when the company reported 100% year-on-year turnover growth and expected to cross ₹150 crore that year across 25 locations in eight states; no revenue or centre count has been published since.
Diagnostics is a capital business dressed as a services one. Pathology labs are cheap to open, but an MRI or PET-CT machine costs several crore and needs a shielded room and a radiologist, which is why profitability in the category is a question of utilisation rather than pricing. Tenet’s expansion into states like Bihar, Jharkhand and Odisha, where advanced imaging is thin, is a bet that being early with a PET-CT in an underserved district is a durable edge, since the next operator into that market faces the same equipment bill against a smaller share of demand.
The investor pairing is worth reading closely: Blue Earth Capital is a limited partner in Tata Capital’s healthcare fund rather than an independent co-investor, and the two firms have structured a round this way before, in a $9 million investment into Apex Kidney Care in early 2025. Three years without an updated revenue figure means Tenet is being priced against a target rather than a result.
